Physician profile
Jason Stepkovitch
NPI 1730227315
$1,747.52
in general payments reported to CMS, 2019-2025
13 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.78 · 2020: $45.67 · 2021: $25.93 · 2022: $246 · 2023: $407 · 2024: $625 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,397.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $822.81 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $335.41 | 2019-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $166.96 | 2021-2025 | Rexulti |
| Axsome Therapeutics, INC. | $107.65 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $98.37 | 2022-2025 | Trintellix |
| Allergan, INC. | $45.67 | 2020 | |
| Lundbeck LLC | $36.42 | 2024 | Rexulti |
| Neurocrine Biosciences, INC. | $31.24 | 2025 | |
| Corcept Therapeutics | $24.88 | 2025 | Korlym |
| Exact Sciences Corporation | $24.51 | 2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $19.19 | 2025 | Zepbound |
| Teva Pharmaceuticals USA, INC. | $18.83 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Stepkovitch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.